Advanced Search

Transplant Rejection Stocks List

Symbol Grade Name % Change
ALKS D Alkermes plc 2.81
BMY B Bristol-Myers Squibb Company 0.99
CDNA C CareDx, Inc. 3.32
View As Page of Charts
Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Attention Deficit Atypical Antipsychotics Biopharmaceutical Products Blood Test Bristol Myers Squibb Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinical Medicine

Related ETFs - A few ETFs which own one or more of the above listed Transplant Rejection stocks.

Symbol Grade Name Weight
FTXH D First Trust Nasdaq Pharmaceuticals ETF 9.33
FTXN C First Trust Nasdaq Oil & Gas ETF 9.33
PBE C PowerShares Dynamic Biotech & Genome 5.26
ARKG D ARK Genomic Revolution Multi-Sector ETF 5.21
PPH C Market Vectors Pharmaceutical ETF 5.11
View all Transplant Rejection related ETFs...
Compare ETFs
  • Compare FTXH to ARKG
  • Compare FTXH to FTXN
  • Compare FTXN to ARKG

    • Recent Signals

    Date Stock Signal Type
    2021-04-15 ALKS Crossed Above 20 DMA Bullish
    2021-04-15 ALKS 50 DMA Resistance Bearish
    2021-04-15 ALKS Bollinger Band Squeeze Range Contraction
    2021-04-15 ALKS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
    2021-04-15 BMY Bollinger Band Squeeze Range Contraction
    2021-04-15 CDNA Crossed Above 50 DMA Bullish
    2021-04-15 CDNA 180 Bullish Setup Bullish Swing Setup

    Recent News for Transplant Rejection Stocks

    Date Stock Title
    Apr 15 BMY Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC
    Apr 15 BMY The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
    Apr 14 BMY Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
    Apr 14 ALKS Is ALKS Stock A Buy or Sell?
    Apr 13 BMY Bristol-Myers raised to buy at Truist on pipeline strength
    Apr 13 BMY Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline
    Apr 13 BMY IRhythm extends losses as more downgrades pile up, Aphria cut to neutral after earnings miss; and more in today’s analyst action
    Apr 13 BMY Bristol-Myers Upgraded to Buy at Truist on Pipeline Strength
    Apr 10 BMY Bristol Myers unveils positive data for Opdivo in late-stage lung cancer study
    Apr 10 BMY Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
    Apr 9 BMY Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
    Apr 9 BMY Sanofi confirms partial response for cancer therapy in mid-stage study
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Attention Deficit Atypical Antipsychotics Biopharmaceutical Products Blood Test Bristol Myers Squibb Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinical Medicine

    Transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Transplant rejection can be lessened by determining the molecular similitude between donor and recipient and by use of immunosuppressant drugs after transplant.

    More about Transplant Rejection
    Browse All Tags